CUPERTINO, Calif., Oct. 30, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that it will report
third quarter and nine months ended September 30, 2019 financial results and host a
conference call after the market close on Monday, November 4, 2019.
Monday November
4 @ 4:30pmET/1:30 p.m. Pacific Time
|
Toll Free:
|
877-407-0784
|
International:
|
201-689-8560
|
Conference
ID:
|
13695661
|
Webcast:
|
http://public.viavid.com/index.php?id=136610
|
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical entity
in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally bioavailable
small molecule, DUR-928 has been shown in preclinical studies to
play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may include
acute organ injury such as alcoholic hepatitis (AH) and acute
kidney injury (AKI), chronic hepatic diseases such as nonalcoholic
steatohepatitis (NASH), and inflammatory skin conditions such as
psoriasis and atopic dermatitis. DURECT's advanced oral and
injectable delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. Key product candidates in this category include
POSIMIR® (bupivacaine extended-release solution), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery, a
long-acting injectable SABER-based HIV investigational product
being developed with Gilead. For more information about DURECT,
please visit www.durect.com.
DURECT Forward-Looking Statement
This press release includes forward-looking statements,
including the potential use of DUR-928 to treat AH, AKI, chronic
hepatic diseases such as NASH, and inflammatory skin disorders such
as psoriasis and atopic dermatitis, as well as statements regarding
the potential use of POSIMIR to treat post-surgical pain and the
development of a SABER-based HIV investigational product.
These forward-looking statements involve risks and uncertainties
that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risk that future trials of
DUR-928, including those in AH, NASH and psoriasis, may not yield
positive results, potential adverse effects arising from the
testing or use of DUR-928, the risk that the FDA may not approve
the POSIMIR NDA, our ability to meet milestones in the development
of an injectable SABER-based HIV investigational product and the
risk that Gilead will terminate the development of this product,
our ability to avoid infringing patents held by other parties and
secure and defend our own patents, and our ability to manage and
obtain capital to fund our operations and expenses. Further
information regarding these and other risks is included in DURECT's
Form 10-Q filed with the Securities and Exchange Commission on
August 2, 2019 under the heading
"Risk Factors."
NOTE: POSIMIR® and SABER® are
trademarks of DURECT Corporation. DUR-928 and POSIMIR are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities.
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-third-quarter-2019-financial-results-and-provide-business-update-on-november-4-300947699.html
SOURCE DURECT Corporation